



SPANISH ASSOCIATION OF PAEDIATRICS

Pulse oximetry screening of critical congenital heart defects in the neonatal period. The Spanish National Neonatal Society recommendation[☆]



Manuel Sánchez Luna^{a,*}, Alejandro Pérez Muñozuri^b, Ester Sanz López^a, José Luis Leante Castellanos^c, Isabel Benavente Fernández^d, César W. Ruiz Campillo^e, M. Dolores Sánchez Redondo^f, Máximo Vento Torres^g, Segundo Rite Gracia^h, on behalf of Comité de Estándares de la Sociedad Española de Neonatología

^a Hospital General Universitario Gregorio Marañón, Universidad Complutense de Madrid, Madrid, Spain

^b Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, La Coruña, Spain

^c Hospital Universitario Santa Lucía, Cartagena, Murcia, Spain

^d Hospital Universitario Puerta del Mar, Cádiz, Spain

^e Hospital Universitario Vall d'Hebron, Barcelona, Spain

^f Complejo Hospitalario de Toledo, Toledo, Spain

^g Hospital Universitario y Politécnico de La Fe, Valencia, Spain

^h Hospital Universitario Miguel Servet, Zaragoza, Spain

Received 22 May 2017; accepted 30 June 2017

Available online 29 December 2017

KEYWORDS

Screening;
Congenital heart
defects;
Newborn;
Pulse oximetry

Abstract Due to its severity, as well as the consequences of a late diagnosis, critical congenital heart defects (CCHD) represent a challenging situation, making an early diagnosis necessary and ideally before symptoms appear when circulatory collapse or death of the newborn can occur.

Due to this, a prenatal and very early postnatal diagnosis is very important. Prenatal ultrasound screening and physical examination of the newborn can miss a considerable number of CCHD cases. Pulse oximetry screening has been demonstrated to be an effective, non-invasive, inexpensive, and well accepted tool in the early diagnosis of CCHD.

[☆] Please cite this article as: Sánchez Luna M, Pérez Muñozuri A, Sanz López E, Leante Castellanos JL, Benavente Fernández I, Ruiz Campillo CW, et al. Cribado de cardiopatías congénitas críticas en el periodo neonatal. Recomendación de la Sociedad Española de Neonatología. An Pediatr (Barc). 2018;88:112.e1–112.e6.

* Corresponding author.

E-mail address: mssluna@salud.madrid.org (M. Sánchez Luna).

PALABRAS CLAVE

Cribado;
 Cardiopatías
 congénitas;
 Recién nacidos;
 Pulsioximetría

The Spanish National Society of Neonatology, through its Standards Committee, and based on the current evidence, recommend the implementation of pulse oximetry screening of CCHD in Spain, and then to offer the best therapy possible to these newborn infants.

© 2017 Asociación Española de Pediatría. Published by Elsevier España, S.L.U. All rights reserved.

Cribado de cardiopatías congénitas críticas en el periodo neonatal. Recomendación de la Sociedad Española de Neonatología

Resumen Debido a su gravedad y a las consecuencias de un diagnóstico tardío, los defectos cardíacos congénitos críticos (DCCC) representan un reto, por lo que es necesario su diagnóstico muy precoz, idealmente antes del comienzo de los síntomas clínicos, que normalmente preceden al colapso circulatorio o muerte del recién nacido.

Por ello es importante su diagnóstico prenatal y posnatal muy precoz; sin embargo, tanto el diagnóstico por ecocardiografía foetal como la exploración física del recién nacido pueden ser insuficientes para diagnosticar un número importante de estos DCCC. El cribado de DCCC mediante el uso de pulsioximetría ha demostrado ser un método eficaz, no invasivo y de bajo coste, además de bien tolerado, para detectar a recién nacidos asintomáticos y afectados de DCCC en las primeras horas después del nacimiento.

La Sociedad Española de Neonatología, a través de su Comisión de Estándares, hace una recomendación, basada en la evidencia actual, para la implementación en nuestro medio de la pulsioximetría como cribado neonatal de DCCC, y poder ofrecer a estos recién nacidos el mejor tratamiento posible en cada caso.

© 2017 Asociación Española de Pediatría. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

In 2011, the United States Department of Health recommended the use of pulse oximetry (PO) for screening of critical congenital heart defects (CCHDs),¹ followed by the development of consensus guidelines by a work group.^{2,3} Providers from different countries are advocating for recommending such screening in Europe.⁴

This document of the Standards Committee of the Sociedad Española de Neonatología (Spanish Society of Neonatology) endorses the recommendation of screening full term or late preterm newborns who are asymptomatic and do not require admission to a neonatal unit. The purpose of this measure is to reduce the risk of delays in the diagnosis of CCHDs, defined as congenital heart defects requiring invasive intervention or resulting in death in the first 30 days of life.⁵

Methods

We conducted a systematic review, searching for sources by means of MeSH and free text terms in the Medline and ISI Web of Knowledge databases.

We determined the quality of the evidence and the strength of recommendation according to the levels of evidence established by the Oxford Centre for Evidence-Based Medicine (<http://www.cebm.net>) and the grades of

recommendations established by the Canadian Task Force on Preventive Health Care.⁶

Rationale for screening

The incidence of moderate and severe congenital heart defects is of 6 in 1000 live births (19/1000 with the inclusion of bicuspid aortic valve), while the overall incidence of congenital heart disease is of 75 in 1000 live births.⁷

The reported incidence of CCHDs ranges between 2.3 cases in 1000 live births and 1 case in 26,000 live births (25% of the total).^{5,7} The diagnosis of CCHDs is delayed in 30% of cases.⁸

There is evidence that the sensitivity of foetal echocardiography is low (68.1%; 95% CI, 59.6–75.5).⁹ While the diagnostic yield of prenatal echocardiography may be higher in some facilities, their experience cannot be generalised,^{10,11} and a study conducted in a population similar to that of Spain found that only 60% of cases of CCHDs were detected prenatally by this method.¹²

The physical examination fails to detect up to 20–30% of CCHDs.^{13,14} Heart murmurs are not always present in CCHDs, and may occur in up to 60% of healthy newborns.^{15,16} Visual assessment of newborn colour is not effective for the detection of hypoxaemia.^{17,18}

The combination of prenatal ultrasound and physical examination may fail to detect between 29.5%⁸ and 20%¹² of CCHDs.

Pulse oximetry for screening of critical congenital heart defects

A 2012 systematic review on this subject included 13 studies with data for 229,421 newborns. It found a sensitivity of PO screening of 76.5%, a specificity of 99.9%, and a false positive rate of 0.14%.¹⁹ The reviewers concluded that PO met the criteria to for universal screening of CCHDs.

Furthermore, PO screening has been well accepted by both health care professionals and families.²⁰

There is sufficient evidence to recommend neonatal screening by PO in the first hours post birth, in addition to prenatal ultrasound and the physical examination (level of evidence A).

Timing of screening

When screening is performed 24 h post birth, the false positive rate can drop to as low as 0.05%, while if performed in the first 24 h after birth, the rate is as high as 0.50%.¹⁹

False positives may be indicative of other diseases, making these false positives “diagnostic.”

An analysis of late screens (>24 h) demonstrated that half of CCHDs manifest in the first 24 h and 20% do so with cardiovascular compromise.²¹

A retrospective review of screens performed before 12 h post birth (applying a UK protocol) detected CCHDs in 9 out of 26,000 live births, with a false positive rate of 0.8%. However, 79% of false positives corresponded to patients with clinically significant conditions that required urgent intervention. The remaining 21% had transitional circulation (real false positives).²²

The Nordic guidelines for pulse oximetry screening²³ recommend its performance before 24 h. Half of the patients in who screen results may have been positive develop symptoms before the screen is performed.^{12,24}

When it comes to home birth, there is evidence of the feasibility of PO screening in the early hours post birth, with a median time point of 1.8 h post birth for the first measurement (interquartile range, 1.3–2.8 h) and 37 h for the second measurement (interquartile range, 27–47 h), and a 1% false positive rate. A high proportion of families find home screening acceptable.^{25,26}

Based on the available evidence, early screening (before 24 h post birth) is recommended over late screening (after 24 h), with screening being most effective when performed in the first 12 h post birth, despite the increase in the number of false positives (level of evidence B).

Sites of testing

Although the aforementioned meta-analysis did not find significant differences in sensitivity between studies that used postductal saturations alone and those that used pre- and postductal saturations,¹⁹ the combination of pre- and postductal saturations increases the detection of left ventricular outflow tract abnormalities.²⁷

Measurement of pre- and postductal saturations achieves detection of a greater number of CCHDs, equivalent to 7 in 100,000 births, although it can also increase the

number of false positives compared to single postductal measurements.^{24,27}

Therefore, the combination of pre- and postductal measurements increases the number of CCHDs detected through screening, with the disadvantage of being more time-consuming (level of evidence B).

Definition of a positive result

Pulse oximetry algorithms establish a saturation threshold of 95%, with saturations of less than 90% considered a strong positive and saturations between 90% and 94% considered a weak positive.

The American Academy of Pediatrics defines a positive screen as a saturation of less than 90% in any extremity, or between 90% and 94% in both the upper and lower extremities, or a difference between hand and foot saturations greater than 3%, on three different measurements, each separated by 1 h, before performing a medical evaluation.³

The algorithm used in the United Kingdom defines a positive screen as a saturation of less than 90% at any time, or ranging between 90% and 94% in the right hand or either foot, or a difference in saturation of more than 2% between the hand and foot, in 2 different measurements 2 h apart, as long as the patient is asymptomatic. In the presence of symptoms, the screen is considered positive.²⁷

In the Nordic algorithm,²³ the screen is positive when saturation in either extremity is less than 90%, or the saturation is between 90% and 94% in both extremities or the difference between the two is greater than 3% in three separate occasions at 30 min intervals.

Thus, the optimal value to define test negativity is 95% saturation or higher, with a strong positive defined as a saturation of less than 90% or the presence of symptoms irrespective of oxygen saturation (level of evidence B),¹⁹ and it is reasonable to apply the criteria for positivity of saturation less than 95% in either extremity or a difference between hand and foot of more than 3% (level of evidence B).

There is disagreement in the interpretation of saturations between 90% and 94%. There are two sets of criteria for considering them positive: when the saturation is less than 95% in both extremities or the difference between the two extremities is greater than 3%,²⁴ and when the saturation is less than 95% in either extremity or the difference between the two extremities is greater than 2%.²⁸ The false positive rate is higher using the first approach as opposed to the second (0.15% vs 0.8%).

There is no consensus as to the clinical approach to take and the need for retesting when the measured saturation is between 90% and 94%. The potential advantage of waiting and repeating the test is the reduction in the number of false positives, and the disadvantage is the delay in diagnosis.

We think that a reasonable approach to a saturation of 90–94% is to perform a medical assessment and repeat the test only once (level of evidence B).

Devices to be used

Screening should be performed with oximeters appropriate for use in newborns that are motion-tolerant and with a high sensitivity under low saturation conditions (level of




Figure 1 Critical congenital heart disease screening algorithm.

evidence B). We also recommend the use of next-generation equipment.^{1,3,29} This is important in the measurement of saturations of more than 70%.³⁰

Expected impact of screening

For screening performed within 24 h, we estimate a hospital admission rate of 6.25 admissions per 1000 births²² and performance of 9 additional echocardiograms per 18,801 screens (42 months of screening).³¹

Cost-effectiveness of screening

Most studies conclude that PO screening of CCHDs is cost-effective. Overall, the estimated cost of each test is of 3.88 to 14 US dollars, with a total cost of screening per patient diagnosed with CCHD of 46,300 US dollars.^{32–34}

Estimated duration and cost of screening

The screening procedure generally takes 5.5–9 min to complete, and can be performed by the staff scheduled on the floor without need for further personnel.^{32,34}

Recommendations

1. A protocol for the postnatal screening of CCHDs in healthy, asymptomatic, non-hospitalised newborns needs to be implemented (A).
2. Pulse oximetry is useful and safe for CCHD screening in newborns (A).
3. The timing of screening affects its sensitivity, with a higher sensitivity the earlier it is performed (A).
 - a. Early screening, within 24 h of birth, reduces the risk of onset with severe or very severe symptoms in CCHD at the expense of a greater number of false positives, although most of the latter are indicative of other disorders that may also require observation, diagnosis and treatment, so early screening is preferable to late screening (>24 h).
 - b. Very early screening (<12 h) may result in an excessive number of false positives, an issue that needs to be weighed at the local level.
 - c. In case of very early discharge, screening should be performed before discharge, regardless of timing.
 - d. It is recommended that the screen be performed between 6 and 24 h post birth (B).
4. Home birth does preclude performance of CCHD screening (B).

5. Measurement of pre- and postductal saturations by PO is recommended to improve the diagnostic yield of screening (B).
6. Screening should be performed with motion-tolerant oximeters intended for use in newborns and validated in low-perfusion conditions (B).
7. A strong positive would correspond to a saturation <90% in the right hand or the foot or the presence of symptoms. In either situation, the newborn should undergo an appropriate medical evaluation (B).
8. A strong negative would correspond to a saturation of $\geq 95\%$ in the right hand and the foot, or a saturation $\geq 95\%$ in any extremity with a difference between the two sites $\leq 3\%$ (B).
9. If the saturation is of 90–94% in the right hand or the foot, or the difference between them is greater than 3%, the measurement should be repeated in 30 min (B). A medical evaluation is recommended at this point (B).
10. If after the second measurement the newborn continues to have a saturation of 90–94% in the right hand or the foot, or the difference between the two is greater than 3%, the screen should be considered positive (B).
11. Basic training should be given to the staff in charge of performing the screens (B).

Fig. 1 presents the algorithm for critical congenital heart defect screening recommended by the Standards Committee of the Sociedad Española de Neonatología.

Conflicts of interest

The authors have no conflicts of interest to declare.

References

1. Sebelius K. Secretary of Health and Human Services recommendation for pulse oximetry screening. Washington, DC: Department of Health and Human Services; 2011. Available from: <http://www.hrsa.gov/advisorycommittees/mchbadvisory/heritabledisorders/recommendations/correspondence/cyanoticheartsecr09212011.pdf> [accessed 21.09.11].
2. Martin GR, Beekman RH 3rd, Mikula EB, Fasules J, Garg LF, Kemper AR, et al. Implementing recommended screening for critical congenital heart disease. *Pediatrics*. 2013;132:e185–92.
3. Kemper AR, Mahle WT, Martin GR, Cooley WC, Kumar P, Morrow WR, et al. Strategies for implementing screening for critical congenital heart disease. *Pediatrics*. 2011;128:e1259–67.
4. Ewer AK, Granelli AD, Manzoni P, Sánchez Luna M, Martin GR. Pulse oximetry screening for congenital heart defects. *Lancet*. 2013;382:856–7.
5. Schultz AH, Localio AR, Clark BJ, Ravishankar C, Videon N, Kimmel SE. Epidemiologic features of the presentation of critical congenital heart disease: implications for screening. *Pediatrics*. 2008;121:751–7.
6. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. *CMAJ*. 2003;169:207–8.
7. Hoffman JI, Kaplan S. The incidence of congenital heart disease. *J Am Coll Cardiol*. 2002;39:1890–900.
8. Peterson C, Ailes E, Riehle-Colarusso T, Oster ME, Olney RS, Cassell CH, et al. Late detection of critical congenital heart disease among US infants: estimation of the potential impact of proposed universal screening using pulse oximetry. *JAMA Pediatr*. 2014;168:361–70.
9. Liu H, Zhou J, Feng QL, Gu HT, Wan G, Zhang HM, et al. Fetal echocardiography for congenital heart disease diagnosis: a meta-analysis, power analysis and missing data analysis. *Eur J Prev Cardiol*. 2015;22:1531–47.
10. Chang RK, Rodriguez S, Klitzner TS. Screening newborns for congenital heart disease with pulse oximetry: survey of pediatric cardiologists. *Pediatr Cardiol*. 2009;30:20–5.
11. Wren C, Reinhardt Z, Khawaja K. Twenty-year trends in diagnosis of life-threatening neonatal cardiovascular malformations. *Arch Dis Child Fetal Neonatal Ed*. 2008;93:F33–5.
12. Riede FT, Wörner C, Dähnert I, Möckel A, Kostelka M, Schneider P. Effectiveness of neonatal pulse oximetry screening for detection of critical congenital heart disease in daily clinical routine – results from a prospective multicenter study. *Eur J Pediatr*. 2010;169:975–81.
13. Górska-Kot A, Błaz W, Pszeniczna E, Rusin J, Materna-Kiryłuk A, Homa E, et al. Trends in diagnosis and prevalence of critical congenital heart defects in the Podkarpatie province in 2002–2004, based on data from the Polish Registry of Congenital Malformations. *J Appl Genet*. 2006;47:191–4.
14. Meberg A, Andreassen A, Brunvand L, Markestad T, Moster D, Nietsch L, et al. Pulse oximetry screening as a complementary strategy to detect critical congenital heart defects. *Acta Paediatr*. 2009;98:682–6. <http://dx.doi.org/10.1111/j.1651-2227.2008.01199.x>.
15. Valmari P. Should pulse oximetry be used to screen for congenital heart disease? *Arch Dis Child Fetal Neonatal Ed*. 2007;92:F219–24.
16. Singh A, Desai T, Miller P, Rasiah SV. Benefits of pre-discharge echocardiography service for postnatal heart murmurs. *Acta Paediatr*. 2012;101:e333–6.
17. Hoffman JI. It is time for routine neonatal screening by pulse oximetry. *Neonatology*. 2011;99:1–9.
18. O'Donnell CP, Kamlin CO, Davis PG, Carlin JB, Morley CJ. Clinical assessment of infant colour at delivery. *Arch Dis Child Fetal Neonatal Ed*. 2007;92:F465–7.
19. Thangaratinam S, Brown K, Zamora J, Khan KS, Ewer AK. Pulse oximetry screening for critical congenital heart defects in asymptomatic newborn babies: a systematic review and meta-analysis. *Lancet*. 2012;379:2459–64.
20. Powell R, Pattison HM, Bhoyar A, Furnston AT, Middleton LJ, Daniels JP, et al. Pulse oximetry screening for congenital heart defects in newborn infants: an evaluation of acceptability to mothers. *Arch Dis Child Fetal Neonatal Ed*. 2013;98:F59–63.
21. Brown KL, Ridout DA, Hoskote A, Verhulst L, Ricci M, Bull C. Delayed diagnosis of congenital heart disease worsens preoperative condition and outcome of surgery in neonates. *Heart*. 2006;92:1298–302.
22. Singh A, Rasiah SV, Ewer AK. The impact of routine pre-discharge pulse oximetry screening in a regional neonatal unit. *Arch Dis Child Fetal Neonatal Ed*. 2014;99:F297–302.
23. De-Wahl Granelli A, Meberg A, Ojala T, Steensberg J, Oskarsson G, Mellander M. Nordic pulse oximetry screening – implementation status and proposal for uniform guidelines. *Acta Paediatr*. 2014;103:1136–42.
24. de-Wahl Granelli A, Wennergren M, Sandberg K, Mellander M, Bejlum C, Inganäs L, et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. *BMJ*. 2009;338:a3037.
25. Narayan IC, Blom NA, Bourgonje MS, Haak MC, Smit M, Posthumus F, et al. Pulse oximetry screening for critical congenital heart disease after home birth and early discharge. *J Pediatr*. 2016;170:188–92.
26. Narayan IC, Kaptein AA, Hogewoning JA, Blom NA, Te Pas AB. Maternal acceptability of pulse

- oximetry screening at home after home birth or very early discharge. *Eur J Pediatr.* 2017;176:669–72, <http://dx.doi.org/10.1007/s00431-017-2883-2>.
27. Ewer AK, Furnston AT, Middleton LJ, Deeks JJ, Daniels JP, Pattison HM, et al. Pulse oximetry as a screening test for congenital heart defects in newborn infants: a test accuracy study with evaluation of acceptability and cost-effectiveness. *Health Technol Assess.* 2012;16:v–v184, <http://dx.doi.org/10.3310/hta16020>, 1–184.
 28. Ewer AK, Middleton LJ, Furnston AT, Bhojar A, Daniels JP, Thangaratinam S, et al., PulseOx Study Group. Pulse oximetry screening for congenital heart defects in newborn infants (PulseOx): a test accuracy study. *Lancet.* 2011;378:785–94.
 29. U.S. Food and Drug Administration. Pulse oximeters – premarket notification submissions [510(k)s]: guidance for Industry and Food and Drug Administration staff; 2013, March 4. Available from: <https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM081352.pdf>
 30. Dawson JA, Saraswat A, Simionato L, Thio M, Kamlin CO, Owen LS, et al. Comparison of heart rate and oxygen saturation measurements from Masimo and Nellcor pulse oximeters in newly born term infants. *Acta Paediatr.* 2013;102:955–60.
 31. Bhola K, Kluckow M, Evans N. Post-implementation review of pulse oximetry screening of well newborns in an Australian tertiary maternity hospital. *J Paediatr Child Health.* 2014;50:920–5.
 32. Kochilas LK, Lohr JL, Bruhn E, Borman-Shoap E, Gams BL, Pylipow M, et al. Implementation of critical congenital heart disease screening in Minnesota. *Pediatrics.* 2013;132:e587–94.
 33. Griebisch I, Knowles RL, Brown J, Bull C, Wren C, Dezateux CA. Comparing the clinical and economic effects of clinical examination, pulse oximetry, and echocardiography in newborn screening for congenital heart defects: a probabilistic cost-effectiveness model and value of information analysis. *Int J Technol Assess Health Care.* 2007;23:192–204.
 34. Peterson C, Grosse SD, Glidewell J, Garg LF, van Naarden Braun K, Knapp MM, et al. A public health economic assessment of hospitals' cost to screen newborns for critical congenital heart disease. *Public Health Rep.* 2014;129:86–93.